Trials / Terminated
TerminatedNCT00790296
Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue
A Pilot, Randomized Double-Blind Placebo-Controlled Crossover Study of Synthetic Thyrotropin Releasing Hormone (TRH) Administration for the Treatment of Fatigue in Patients With Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- UConn Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue. The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thyrotropin releasing hormone (TRH) | 0.5mg and 1.5mg |
| DRUG | Placebo | Saline |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2010-02-01
- Completion
- 2010-03-01
- First posted
- 2008-11-13
- Last updated
- 2017-12-28
- Results posted
- 2011-05-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00790296. Inclusion in this directory is not an endorsement.